Lineage Cell Therapeutics is a biotechnology business based in the US. Lineage Cell Therapeutics shares (LCTX) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.60 – a decrease of 30.59% over the previous week. Lineage Cell Therapeutics employs 68 staff and has a trailing 12-month revenue of around $6.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.60 |
|---|---|
| 52-week range | $0.50 - $1.61 |
| 50-day moving average | $0.88 |
| 200-day moving average | $1.02 |
| Wall St. target price | $4.57 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.6414 from 2024-11-20
| 1 week (2024-11-15) | -25.80% |
|---|---|
| 1 month (2024-10-23) | -26.30% |
| 3 months (2024-08-22) | -28.10% |
| 6 months (2024-05-22) | -38.91% |
| 1 year (2023-11-22) | -35.86% |
|---|---|
| 2 years (2022-11-22) | -56.37% |
| 3 years (2021-11-22) | 2.17 |
| 5 years (2019-11-22) | 0.852 |
| Revenue TTM | $6.2 million |
|---|---|
| Gross profit TTM | $14 million |
| Return on assets TTM | -12.86% |
| Return on equity TTM | -35.04% |
| Profit margin | 0% |
| Book value | $0.36 |
| Market Capitalization | $113.3 million |
TTM: trailing 12 months
We're not expecting Lineage Cell Therapeutics to pay a dividend over the next 12 months.
Lineage Cell Therapeutics's shares were split on a 3:1 basis on 30 October 1997 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lineage Cell Therapeutics shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Lineage Cell Therapeutics shares which in turn could have impacted Lineage Cell Therapeutics's share price.
Over the last 12 months, Lineage Cell Therapeutics's shares have ranged in value from as little as $0.5 up to $1.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Lineage Cell Therapeutics's is 1.282. This would suggest that Lineage Cell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.